Charles River Laboratories has expanded its collaboration with The Michael J. Fox Foundation for Parkinson’s Research (MJFF) for the development of small molecule LRRK2 inhibitors. The work will build on previous research that advanced efforts to identify novel small molecule LRRK2 inhibitors. The inhibition of the kinase LRRK2, which has been genetically linked to development of PD, is one of the most promising therapeutic strategies. The goal is to determine optimal dosing strategies to achiev...